Study compares biologic agents in liver-limited RAS wild-type disease

▸ TREATMENT

A retrospective analysis of 241 patients with RAS wild-type metastatic colorectal cancer confined to the liver compared outcomes among patients treated with first-line chemotherapy plus panitumumab, cetuximab, or bevacizumab, evaluating depth of response, objective response rate, disease control rate, and conversion to resectability. (Oncology Research)